Acura receives $300K loans from controlling shareholder; warns of potential shutdown if no funding by Jan 2026

ACURA PHARMACEUTICALS, INC

On Dec 31, Jan 2, and Jan 16, 2026, Acura received $100K each from Abuse Deterrent Pharma (65% owner), bringing note principal to $9.59M.
Note bears 5.25% interest; default rate 7.5%; events of default include bankruptcy and failure to pay within 5 days.
Company states that without additional financing by end of January 2026, it will scale back operations or seek bankruptcy protection.
AD Pharma holds ~65% of Acura's common stock; entity controlled by Mr. Schutte, who directly owns ~13%.
Proceeds fund day-to-day operations; company warns of potential complete loss of shareholder value.

item 1.01 item 2.01 item 2.03 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

ACURA PHARMACEUTICALS, INC incurred loan of $100,000 with Abuse Deterrent Pharma, LLC at 5.25%.

Instrument: loan
Principal: $100,000
Counterparty: Abuse Deterrent Pharma, LLC
Rate: 5.25%
Event: incurrence

Exact text from the filing

On each of December 31, 2025, January 2, 2026 and January 16, 2026 we received loans of $100,000 from Abuse Deterrent Pharma, LLC ("AD Pharma").

View on SEC.gov

306 debt financings filed in the last 30 days. Browse all debt financings →

Source: SEC EDGAR

accession 0001104659-26-005038

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.